Share Share Share

Low-burden TP53 mutations in chronic phase of myeloproliferative neoplasms: association with age, hydroxyurea administration, disease type and JAK2 mutational status

LEUKEMIA

Kubesova, B; Pavlova, S; Malcikova, J; Kabathova, J; Radova, L; Tom, N; Tichy, B; Plevova, K; Kantorova, B; Fiedorova, K; Slavikova, M; Bystry, V; Kissova, J; Gisslinger, B; Gisslinger, H; Penka, M; Mayer, J; Kralovics, R; Pospisilova, S; Doubek, M, 2018: Low-burden TP53 mutations in chronic phase of myeloproliferative neoplasms: association with age, hydroxyurea administration, disease type and JAK2 mutational status. LEUKEMIA 32(2), p. 450 - 461, doi: 10.1038/leu.2017.230

Research Groups:

• CF: Genomics Core Facility
• Medical Genomics

CEITEC authors:

• Karla Plevová, Ph.D.
• Šárka Pavlová, Ph.D.
• Lenka Radová, Ph.D.
• Boris Tichý, Ph.D.
• Vojtěch Bystrý, Ph.D.
• Prof. Jiří Mayer
• Jitka Malčíková, Ph.D.
• Prof. Michael Doubek, Ph.D.
• Prof. Šárka Pospíšilová, Ph.D.